In addition, a meta-analysis encompassing 16 randomized clinical trials indicated that while liraglutide reduced visceral and hepatic fat volume, its effect of EAT reduction did not reach statistical significance ( 171 ).
← all excerpts
Research on epicardial adipose tissue as a metabolic therapeutic target in AF: focus on GLP-1 receptor agonists.
1
—
—